The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced ...

Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked ...

Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in ...

A new study reveals how Lactococcus lactis (L. lactis), a common food bacterium, regulates the production of a key precursor ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

A new tool from the lab of Velia Therapeutics co-founder Alan Saghatelian, Ph.D., has proven capable of scouring genetic data for tiny proteins that may serve as new therapeutic targets, opening the ...

Despite its well-publicised problems, the FDA is a happy place for ASX biotechs seeking drug or device approvals.

The guidelines, based on research published in the AHA's Circulation journal, say that cutting back on these foods reduces a person's risk of having a heart attack, a stroke, type 2 diabetes and ...

Q2 2025 Earnings Call Transcript August 7, 2025 Puma Biotechnology, Inc. beats earnings expectations. Reported EPS is $0.15, ...

Detailed price information for Bicycle Therapeutics Plc ADR (BCYC-Q) from The Globe and Mail including charting and trades.

The 20th anniversary of the 2005 Ashes series is a moment in time: a chance to capture the 12 England winners as they are now ...